Aadi Bioscience (AADI) Set to Announce Quarterly Earnings on Wednesday

Aadi Bioscience (NASDAQ:AADI) will announce its earnings results before the market opens on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.46) per share for the quarter.

Aadi Bioscience (NASDAQ:AADI) last issued its earnings results on Wednesday, August 7th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.17. Aadi Bioscience had a negative return on equity of 66.67% and a negative net margin of 274.77%. The business had revenue of $6.18 million for the quarter, compared to the consensus estimate of $6.33 million. During the same period last year, the business posted ($0.67) EPS. On average, analysts expect Aadi Bioscience to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aadi Bioscience Trading Down 1.5 %

Shares of AADI opened at $1.96 on Thursday. The business’s fifty day simple moving average is $1.90 and its two-hundred day simple moving average is $1.75. Aadi Bioscience has a 12 month low of $1.21 and a 12 month high of $5.70. The company has a market cap of $48.25 million, a price-to-earnings ratio of -0.81 and a beta of 0.70.

Insider Buying and Selling

In related news, Chairman Neil Desai sold 40,000 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $1.71, for a total value of $68,400.00. Following the transaction, the chairman now directly owns 1,171,543 shares of the company’s stock, valued at approximately $2,003,338.53. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders have sold 55,341 shares of company stock valued at $94,770. 37.30% of the stock is owned by company insiders.

Analyst Ratings Changes

Several analysts have commented on AADI shares. TD Cowen downgraded Aadi Bioscience from a “buy” rating to a “hold” rating in a research note on Wednesday, August 21st. Piper Sandler Companies cut Aadi Bioscience from an “overweight” rating to a “neutral” rating and set a $1.75 price target on the stock. in a report on Tuesday, August 27th. Jefferies Financial Group cut Aadi Bioscience from a “buy” rating to a “hold” rating and lowered their price target for the company from $11.00 to $1.50 in a report on Wednesday, August 21st. HC Wainwright reissued a “neutral” rating on shares of Aadi Bioscience in a report on Wednesday, August 21st. Finally, Piper Sandler cut Aadi Bioscience from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $5.00 to $1.75 in a report on Tuesday, August 27th. Five equities research analysts have rated the stock with a hold rating, According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $10.25.

Aadi Bioscience Company Profile

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.